Veradermics (MANE) CEO Reid Waldman Sells 67,500 Shares

What Happened
Waldman Reid Alexander (CEO) sold a total of 67,500 Veradermics (MANE) shares in multiple open-market transactions on 2026-08-17, generating approximately $7,280,713 in proceeds. On the same date he exercised 3,452 options at $12.19 per share (cost ≈ $42,080) and the filing also shows a 3,452-share derivative disposition reported at $0.00. The activity is primarily sales (not a purchase), which is often routine insider selling but does not by itself indicate the CEO’s view of the company.

Key Details

• Transactions date: 2026-08-17; Form 4 filed 2026-08-18 (timely filing).
• Sales breakdown (weighted averages/ranges):
  • 11,527 shares — weighted avg reported $106.72 (transactions ranged $106.07–$107.00) — proceeds $1,230,161. [F1]
  • 25,234 shares — weighted avg $107.53 (range $107.00–$108.00) — proceeds $2,713,412. [F2]
  • 27,490 shares — weighted avg $108.45 (range $108.00–$108.99) — proceeds $2,981,291. [F3]
  • 3,000 shares — weighted avg $109.38 (range $109.02–$109.84) — proceeds $328,140. [F4]
  • 249 shares — reported $111.28 — proceeds $27,709.
• Option exercise: 3,452 shares acquired at $12.19 per share (total cost ≈ $42,080). Footnote F5 states the option was fully vested and exercisable.
• Derivative disposition: 3,452 shares reported disposed at $0.00 (filing does not state reason; such entries often reflect share surrender/net settlement or tax withholding).
• Shares owned after the transactions: not specified in the excerpt provided — see the full Form 4 for post-transaction holdings.
• No 10b5-1 plan, tax-withholding specifics, or late-filing indication are included in the provided notes.

Context

• The filing shows option exercise plus substantial open-market sales on the same day. The exercised shares (3,452) are small relative to total shares sold (67,500), so most proceeds appear to come from selling previously held shares. The reported $0.00 derivative disposition may reflect share surrender for taxes or net settlement, but the filing does not specify.
• Sales by executives are common and can be for many reasons (diversification, liquidity needs, option exercises); purchases are generally considered a stronger signal. This summary is factual and does not infer motive.